Long-term results of Gleevec® published

Results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent, have now been published by investigators. According to the National Cancer Institute, prior to Gleevec’s 2001 FDA approval, fewer than one in three CML patients survived five years past diagnosis. (Mehr in: Cancer News — ScienceDaily)